INTRODUCTION {#s1}
============

As one of the most common malignancies worldwide, hepatocellular carcinoma (HCC) represents the second-leading cause of cancer deaths globally with 745,000 deaths per year \[[@R1]\]. The HCC were categorized into poorly-, moderately-, and well- differentiated types. Hepatic resection is currently the most optimal choice for HCC treatment. However, poorly differentiated HCC has a worse prognosis with high recurrence rate compared to other two types \[[@R2], [@R3]\]. In addition, it is hard to discriminate poorly differentiated HCC from other two types of HCC before treatment. The lack of good diagnostic markers and therapeutic targets has rendered HCC a major challenge.

Recently, high-throughput technologies like RNA sequencing make it possible and easy to illustrate the transcriptome characteristics of cancers including HCC \[[@R4]\]. Some potential biomarkers for HCC were identified using transcriptome sequencing e.g. SERPINA11 whose expression is correlated with pathology stages lack documented expression profiles in liver cancer \[[@R5]\]. Some signaling pathways like cell cycle were also involved via analysis of transcriptome sequencing data \[[@R6]\]. Those studies show a great promise of exploring the molecular basis of HCC.

In this study, we performed transcriptome sequencing for patients with poorly differentiated (PD), moderately differentiated (MD) and well differentiated (WD) HCC. 3 patients diagnosed as HCC of each grades were recruited, respectively. Differentially expressed genes (DEGs) were identified through analysis of transcriptome sequencing data. DEGs were then subjected to gene set enrichment analysis. Furthermore, RT-PCR was performed to validate potential biomarkers in 15 pairs of poorly differentiated tumor and adjacent non-tumorous samples. Our investigation may provide new clues on the molecular event responsible for the progression of HCC and potential biomarkers and therapeutic targets for diagnosis and treatment of HCC patients.

RESULTS {#s2}
=======

Overview of transcriptome sequencing statistics {#s2_1}
-----------------------------------------------

Pair-end second-generation transcriptome sequencing was performed in 9 HCC patients. Sample characteristics were shown in Table [1](#T1){ref-type="table"}. An average of 35,772,695 pair-end 125 bp clean reads was generated (Table [2](#T2){ref-type="table"}). The average mapping rate was 93.17%, resulting an average coverage of depth of 32 × (Table [2](#T2){ref-type="table"}). Expression levels of more than 25,200 genes were calculated using Tophat/Cufflinks ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}). The heatmap of all expressed genes were drawn in Figure [1](#F1){ref-type="fig"}, which showed a big group of differentially expressed genes (DEGs) between tumor and adjacent non-tumorous samples of poorly differentiated HCC.

###### Detailed characteristics of the patients

  Patient    Age        Gender    Hepatitis    Serum AFP level (ng/mL)   Metastasis   Glisson capsule invasion   Tumor size (mm)   Differentiation Grade   Multiple liver nodules
  ---------- ---------- --------- ------------ ------------------------- ------------ -------------------------- ----------------- ----------------------- ------------------------
  ***P1***   ***59***   ***M***   ***HBV***    ***670.1***               ***No***     −                          ***35***          ***Poorly***            \-
  ***P2***   ***50***   ***M***   ***HBV***    ***12483***               ***No***     \+                         ***50***          ***Poorly***            \-
  ***P3***   ***37***   ***M***   ***HBV***    ***4.47***                ***No***     \+                         ***41***          ***Poorly***            \-
  ***M1***   ***59***   ***M***   ***HBV***    ***3.73***                ***No***     −                          ***6***           ***moderately***        \-
  ***M2***   ***69***   ***M***   ***HBV***    ***6.9***                 ***No***     \+                         ***160***         ***moderately***        ***synchronous***
  ***M3***   ***61***   ***M***   ***NBNC***   ***1.11***                ***No***     \+                         ***80***          ***moderately***        \-
  ***W1***   ***62***   ***M***   ***HBV***    ***266.5***               ***No***     \+                         ***32***          ***Well***              \-
  ***W2***   ***76***   ***M***   ***HCV***    ***5.84***                ***No***     \+                         ***70***          ***Well***              \-
  ***W3***   ***19***   ***F***   ***NBNC***   ***2.85***                ***No***     −                          ***29***          ***Well***              \-
  P4         48         M         NBNC         55.1                      Yes          \+                         180               Poorly                  \-
  P5         41         M         HBV          4.7                       Yes          \+                         50                Poorly                  \-
  P6         64         M         HBV          244.6                     Yes          \+                         65                Poorly                  synchronous
  P7         50         M         HBV          3.03                      Yes          \+                         55                Poorly                  synchronous
  P8         47         M         HBV          62.47                     Yes          \+                         105               Poorly                  \-
  P9         64         M         HBV          36541                     Yes          \+                         140               Poorly                  \-
  P10        52         M         HBV          2100                      Yes          −                          35                Poorly                  \-
  P11        52         M         NBNC         5.3                       No           \+                         65                Poorly                  \-
  P12        37         M         HBV          1810                      No           −                          55                Poorly                  \-
  P13        48         M         HBV          2.07                      No           −                          35                Poorly                  \-
  P14        52         F         NBNC         2.45                      No           \+                         22                Poorly                  \-
  P15        58         M         HBV          6.52                      Yes          \+                         58                Poorly                  synchronous
  M4         63         M         HBV          2975                      No           \+                         70                moderately              synchronous
  M5         47         M         HBV          5375                      Yes          \+                         130               moderately              \-
  M6         72         M         HBV          303.8                     No           \+                         40                moderately              synchronous
  M7         66         M         HBV          60500                     No           \+                         50                moderately              \-
  M8         59         M         NBNC         54.84                     No           \+                         26                moderately              \-
  M9         67         M         HBV          321.1                     No           \+                         55                moderately              synchronous
  M10        71         M         HBV          4606                      Yes          \+                         12                moderately              \-
  M11        18         F         HBV          37979                     No           \+                         70                moderately              \-
  M12        45         M         HBV          6528                      No           \+                         60                moderately              synchronous
  M13        61         M         HBV          1.9                       No           \+                         30                moderately              \-
  M14        52         M         HBV          26.53                     No           \+                         20                moderately              \-
  M15        58         F         HBV          2.55                      Yes          \+                         55                moderately              synchronous
  M16        42         M         HBV          3.38                      No           \+                         20                moderately              synchronous
  M17        64         M         HBV          774.2                     No           \+                         10                moderately              \-
  M18        54         F         NBNC         23784                     No           \+                         22                moderately              \-
  W4         72         M         HBV          11.10                     No           \+                         20                Well                    \-
  W5         55         M         HBV          1.82                      No           \+                         34                Well                    \-
  W6         76         M         NBNC         2.1                       No           \+                         34                Well                    \-
  W7         67         M         NBNC         3.30                      No           −                          18                Well                    \-
  W8         50         M         HBV          260.9                     No           −                          25                Well                    \-
  W9         71         M         HBV          11.65                     No           \+                         35                Well                    \-
  W10        74         M         NBNC         5.9                       No           \+                         30                Well                    \-
  W11        39         M         HBV          8.10                      Yes          \+                         22                Well                    synchronous
  W12        63         M         HBV          208                       No           \+                         40                Well                    \-
  W13        48         M         NBNC         3.07                      No           −                          33                Well                    \-
  W14        66         M         HBV          82.81                     No           \+                         34                Well                    \-

Note: The nine samples used for sequencing are labeled in bold and italic.

###### Summary statistics of the transcriptome sequencing

  Patient   Differentiation grade   Sample Type   Total reads     Mapped reads    Total base (bp)   Mapped base (bp)   Mappping ratio   Coverage (X)
  --------- ----------------------- ------------- --------------- --------------- ----------------- ------------------ ---------------- --------------
  P1        Poorly                  T             35,930,408      33,819,287      4,491,301,000     4,227,410,875      94.12%           33
  N         34,902,228              32,863,973    4,362,778,500   4,107,996,625   94.16%            32                                  
  P2        Poorly                  T             35,315,378      33,125,921      4,414,422,250     4,140,740,125      93.80%           32
  N         34,383,802              32,279,443    4,297,975,250   4,034,930,375   93.88%            31                                  
  P3        Poorly                  T             35,532,658      33,258,212      4,441,582,250     4,157,276,500      93.60%           32
  N         34,537,914              32,152,860    4,317,239,250   4,019,107,500   93.09%            31                                  
  M1        Moderately              T             34,566,526      32,670,216      4,320,815,750     4,083,777,000      94.51%           31
  N         35,384,486              33,407,169    4,423,060,750   4,175,896,125   94.41%            32                                  
  M2        Moderately              T             34,564,642      32,385,294      4,320,580,250     4,048,161,750      93.69%           31
  N         34,771,048              32,792,475    4,346,381,000   4,099,059,375   94.31%            32                                  
  M3        Moderately              T             35,371,920      32,571,695      4,421,490,000     4,071,461,875      92.08%           31
  N         35,959,532              32,990,753    4,494,941,500   4,123,844,125   91.74%            32                                  
  W1        Well                    T             34,762,386      32,701,011      4,345,298,250     4,087,626,375      94.07%           31
  N         35,314,918              33,021,170    4,414,364,750   4,127,646,250   93.50%            32                                  
  W2        Well                    T             35,610,444      32,509,118      4,451,305,500     4,063,639,750      91.29%           31
  N         34,637,398              31,280,461    4,329,674,750   3,910,057,625   90.31%            30                                  
  W3        Well                    T             42,279,434      39,097,967      5,284,929,250     4,887,245,875      92.50%           38
  N         40,083,384              36,852,292    5,010,423,000   4,606,536,500   91.90%            35                                  
  Average                                         35,772,695      33,321,073      4,471,586,847     4,165,134,146      93.17%           32

Note: T and N represent tumor and adjacent non-tumor tissue, respectively.

![Heatmap of expressed genes\
For the sample labels, N and T represented matched adjacent non-tumor tissue specimens and tumor tissue specimens respectively. Each row represented of Z scores of genes across different samples.](oncotarget-08-35973-g001){#F1}

Identification of DEGs between tumor and adjacent non-tumor tissues {#s2_2}
-------------------------------------------------------------------

We next detected DEGs between tumor and adjacent non-tumorous samples of poorly differentiated, moderately differentiated and well differentiated HCC. Through paired-*T* test analysis (*P value* \< 0.05, Fold change \> 2), a total of 1020 DEGs were detected including 372 up-regulated genes (313, 47 and 12 for poorly-, moderately- and well-differentiated HCC, respectively) and 648 down-regulated genes (368, 249 and 31 for poorly-, moderately- and well-differentiated HCC, respectively) (Figure [2A](#F2){ref-type="fig"}; [Supplementary Table 2](#SD3){ref-type="supplementary-material"}). Only 1 down-regulated gene (CD44) was overlapped in all 3 grades. Top 20 up-regulated genes and Top 20 down-regulated genes of poorly differentiated HCC were shown in Table [3](#T3){ref-type="table"} and Table [4](#T4){ref-type="table"}, respectively.

###### Top 20 up-regulated genes of poorly differentiated HCC

  Entrez_ID   Gene Symbol   N1       N2       N3       T1       T2       T3       Group mean \_exp_N   Group mean \_exp_T   Group \_log2FC   Group ttest \_*p* value
  ----------- ------------- -------- -------- -------- -------- -------- -------- -------------------- -------------------- ---------------- -------------------------
  10130       PDIA6         116.76   123.98   126.57   255.14   260.71   263.04   122.44               259.63               1.08             1.90E-05
  578         BAK1          6.41     5.00     9.99     20.24    18.51    23.98    7.14                 20.91                1.43             1.03E-04
  1650        DDOST         53.21    72.67    59.72    115.80   139.67   121.44   61.87                125.64               1.01             6.57E-04
  2786        GNG4          0.04     0.02     0.23     1.84     1.90     2.21     0.10                 1.98                 1.45             7.97E-04
  84933       C8orf76       6.03     5.11     6.90     24.33    21.27    23.79    6.01                 23.13                1.78             1.35E-03
  22996       TTC39A        0.04     0.29     0.46     2.38     2.35     2.73     0.26                 2.49                 1.46             1.46E-03
  5691        PSMB3         119.36   132.67   145.10   301.66   342.81   347.47   132.37               330.64               1.31             1.74E-03
  54522       ANKRD16       1.87     2.67     2.10     6.20     7.28     7.16     2.21                 6.88                 1.29             2.04E-03
  28998       MRPL13        13.72    14.12    18.44    69.51    61.37    73.26    15.43                68.05                2.07             2.62E-03
  50854       C6orf48       28.97    70.17    66.97    111.29   140.99   150.56   55.37                134.28               1.26             2.64E-03
  3094        HINT1         270.52   305.61   289.43   605.26   590.80   625.23   288.52               607.10               1.07             2.74E-03
  4738        NEDD8         131.06   138.11   152.30   291.78   329.80   338.89   140.49               320.16               1.18             2.84E-03
  57538       ALPK3         0.47     1.81     1.41     3.16     4.41     3.61     1.23                 3.73                 1.08             3.65E-03
  65244       SPATS2        2.33     3.32     3.91     6.11     7.99     8.07     3.18                 7.39                 1.00             3.73E-03
  8624        PSMG1         15.75    16.67    25.69    37.42    39.74    44.17    19.37                40.44                1.02             4.12E-03
  8836        GGH           61.61    26.09    42.65    124.45   87.68    117.67   43.45                109.93               1.32             4.12E-03
  23640       HSPBP1        7.35     11.32    9.61     19.05    25.08    24.27    9.42                 22.80                1.19             4.27E-03
  79075       DSCC1         0.34     0.51     1.13     4.16     4.12     4.17     0.66                 4.15                 1.63             4.36E-03
  5591        PRKDC         5.80     5.46     7.02     17.28    15.77    16.09    6.09                 16.38                1.29             4.50E-03
  84701       COX4I2        0.22     1.13     0.23     3.16     4.83     3.73     0.53                 3.91                 1.69             4.56E-03

Note: T1, T2, T3 represent tumor tissue of P1, P2, P3 with poorly differentiated HCC, respectively; N1, N2, N3 represent adjacent non-tumor tissue of P1, P2, P3 with poorly differentiated HCC, respectively.

###### Top 20 down-regulated genes of poorly differentiated HCC

  -------------------------------------------------------------------------------------------------------------------------------------------------------
  Entrez_ID   Gene Symbol   N1        N2        N3        T1        T2       T3       Group mean \_exp_N   Group mean \_exp_T   Group\     Group ttest\
                                                                                                                                \_log2FC   \_*p* value
  ----------- ------------- --------- --------- --------- --------- -------- -------- -------------------- -------------------- ---------- --------------
  83854       ANGPTL6       25.01     28.16     28.36     4.67      8.61     8.62     27.18                7.30                 −1.76      1.44E-04

  2706        GJB2          14.85     15.50     12.98     2.92      3.18     1.25     14.44                2.45                 −2.16      2.00E-04

  23002       DAAM1         5.54      5.70      6.63      1.39      1.70     2.41     5.96                 1.83                 −1.30      2.23E-04

  8671        SLC4A4        10.64     9.24      9.18      2.04      1.21     1.14     9.68                 1.46                 −2.12      5.10E-04

  389643      NUGGC         8.92      9.30      8.32      1.61      2.46     1.52     8.85                 1.86                 −1.78      5.44E-04

  80824       DUSP16        18.19     15.58     14.62     8.60      6.06     5.75     16.13                6.80                 −1.13      5.97E-04

  1756        DMD           19.00     20.67     22.49     1.15      4.00     4.22     20.72                3.12                 −2.40      7.46E-04

  2244        FGB           4822.00   2846.01   2754.51   2475.77   484.91   192.48   3474.17              1051.05              −1.72      8.24E-04

  56907       SPIRE1        3.97      5.48      6.04      0.96      2.07     2.81     5.17                 1.95                 −1.06      1.29E-03

  283537      SLC46A3       39.62     40.22     43.44     4.31      1.39     8.81     41.09                4.84                 −2.85      1.29E-03

  132671      SPATA18       2.87      2.41      2.67      0.12      0.02     0.20     2.65                 0.11                 −1.71      1.81E-03

  1003        CDH5          14.79     13.86     23.11     2.30      1.73     9.11     17.25                4.38                 −1.76      1.97E-03

  4051        CYP4F3        116.69    77.42     71.59     57.44     8.09     7.12     88.57                24.21                −1.83      2.04E-03

  9953        HS3ST3B1      5.67      5.24      4.49      0.63      0.47     0.18     5.13                 0.43                 −2.10      2.05E-03

  10894       LYVE1         43.68     40.34     38.97     0.56      3.11     0.76     41.00                1.48                 −4.08      2.12E-03

  57188       ADAMTSL3      5.57      4.39      4.54      1.40      0.08     0.87     4.83                 0.78                 −1.71      2.25E-03

  152926      PPM1K         3.52      3.35      4.35      0.93      0.81     1.39     3.74                 1.04                 −1.21      2.27E-03

  8658        TNKS          6.36      5.58      6.40      2.33      2.03     2.20     6.11                 2.19                 −1.16      2.44E-03

  116519      APOA5         208.64    134.96    119.75    88.24     9.53     14.19    154.45               37.32                −2.02      2.58E-03

  90417       KNSTRN        2.17      3.28      4.17      7.96      6.80     8.81     3.21                 7.85                 1.07       1.94E-02
  -------------------------------------------------------------------------------------------------------------------------------------------------------

Note: T1, T2, T3 represent tumor tissue of P1, P2, P3 with poorly differentiated HCC, respectively; N1, N2, N3 represent adjacent non-tumor tissue of P1, P2, P3 with poorly differentiated HCC, respectively.

![Functional characterization of DEGs\
(**A**) Venn diagram of DEGs between poorly differentiated (PD), moderately differentiated (MD) and well differentiated (WD) HCC. (**B**) Functional enrichment analysis of DEGs of poorly differentiated HCC. (**C**) Top 12 perturbations with high negative connectivity scores with DEGs of poorly differentiated HCC. (**D**) Venn diagram of DEGs between PD HCC tumor tissues and MD&WD tumor tissues, DEGs of PD HCC, DEGs of MD HCC, and DEGs of WD HCC.](oncotarget-08-35973-g002){#F2}

Significantly enriched functions for DEGs of poorly differentiated HCC {#s2_3}
----------------------------------------------------------------------

DEGs of poorly differentiated HCC were subjected to functional enrichment analyses to illustrate their biological function characteristics using Enrichr tool \[[@R7]\]. The top enriched terms for categories were shown in Figure [2B](#F2){ref-type="fig"} (*P value* \< 0.1). From Human Gene Atlas and Cancer Cell Line Encyclopedia, those DEGs were enriched in liver tissue and various liver cancer cells. The enriched biological process and pathway included metabolism, cell cycle, translation and blood coagulation. The DEGs tended to lie in mitochondrial, chromosome and ribosome. From the ENCODE TF ChIP-seq data, 5 transcription factors in liver cancer cell HEPG2 were enriched to regulate the poorly differentiated DEGs.

Potential perturbations for reverse of abnormal gene expression change of poorly differentiated HCC {#s2_4}
---------------------------------------------------------------------------------------------------

LINCS is a collection of signatures of gene expression for a broad range of conditions such as drug treatment, ligand treatment, gene knockdown, and gene over-expression in many different types of human cells \[[@R8]\]. We inputted the up-regulated genes and down-regulated genes into lincscloud to find perturbations that had opposite gene expression change with differentiated HCC. Top 12 perturbations with high negative connectivity scores (Figure [2C](#F2){ref-type="fig"}), which included 4 compounds, 7 knockdown genes and 1 over-expression gene.

Comparison of tumor tissues between PD HCC and MD&WD HCC {#s2_5}
--------------------------------------------------------

Besides DEGs between tumor and adjacent non-tumorous samples, we compared tumor tissues between PD HCC and MD&WD HCC. As a result, 725 differentially expressed genes were identified ([Supplementary Table 2](#SD3){ref-type="supplementary-material"}); among them, 209 were identified as DEGs when comparing tumor and adjacent non-tumorous samples (Figure [2D](#F2){ref-type="fig"}). Gene ontology enrichment analysis was also done based on this 725-gene list. Similarly, these genes were enriched in organelle fission, mitotic nuclear division, positive regulation of cell cycle phase transition and serine family amino acid catabolic process.

Validation of DEGs specific for poorly differentiated HCC by RT-PCR {#s2_6}
-------------------------------------------------------------------

4 DEGs specific for poorly differentiated HCC as well as related with cell cycle or proliferation were validated by RT-PCR. In the discovery phase, the expressions of NOVA1, NSMCE2 and KIAA0196 were significantly up-regulated, while expression of AQP9 was significantly down-regulated in poorly differentiated samples, as compared with that in adjacent non-tumorous samples, moderately differentiated samples and well differentiated samples (*P* \< 0.05) (Table [5](#T5){ref-type="table"}). RT-PCR results showed that all these 4 genes were successfully validated (Figure [3](#F3){ref-type="fig"}), and the dysregulation trend matched with those observed in the RNA-seq data.

###### 4 DEGs specific for poorly differentiated HCC

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Entrez ID   Gene Symbol   N1       N2       N3       N4       N5       N6       N7       N8       N9       T1      T2      T3      T4       T5       T6       T7       T8       T9       *t* test\
                                                                                                                                                                                           *p* value
  ----------- ------------- -------- -------- -------- -------- -------- -------- -------- -------- -------- ------- ------- ------- -------- -------- -------- -------- -------- -------- -----------
  4857        NOVA1         0.45     0.92     0.60     0.46     0.33     0.60     0.34     0.34     0.68     8.90    4.66    6.21    0.53     0.54     2.34     0.93     0.14     0.19     3.92E-022

  286053      NSMCE2        7.21     11.26    12.07    10.67    7.07     14.89    10.64    14.13    7.46     49.75   80.27   61.78   13.90    19.52    17.62    16.57    28.10    10.60    2.74E-02

  9897        KIAA0196      11.23    9.64     12.62    7.93     9.70     11.73    7.95     13.44    7.68     29.40   34.53   27.14   10.02    5.18     10.03    11.86    14.91    6.73     6.78E-03

  55039       AQP9          333.45   217.87   178.65   419.54   364.99   429.47   445.80   385.51   257.32   25.06   15.89   19.74   174.82   215.45   188.60   152.81   199.10   232.73   1.32E-03
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Note: N1, N2, N3 and T1, T2, T3 represent adjacent non-tumor tissue and tumor tissue of P1, P2, P3 with poorly differentiated HCC, respectively. N4, N5, N6 and T4, T5, T6 represent adjacent non-tumor tissue and tumor tissue of M1, M2, M3 with moderately differentiated HCC, respectively. N7, N8, N9 and T7, T8, T9 represent adjacent non-tumor tissue and tumor tissue of W1, W2, W3 with well differentiated HCC, respectively. *p* value refers to T1, T2, T3 vs N1, N2, N3, N4, N5, N6, N7, N8, N9, T4, T5, T6, T7, T8, T9 by *t* test.

![RT-PCR validation of 4 DEGs specific for poorly differentiated HCC\
GAPDH mRNA was used as an internal control. Expression data were obtained as 2^−ΔΔCT^ relative to adjacent non-tumor tissue values. N~PD~ and T~PD~ represented matched adjacent non-tumor tissue specimens (*n* = 15) and poorly differentiated HCC tissue specimens (*n* = 15) respectively. N~MD~ and T~MD~ represented matched adjacent non-tumor tissue specimens (*n* = 18) and moderately differentiated HCC tissue specimens (*n* = 18) respectively. N~WD~ and T~WD~ represented matched adjacent non-tumor tissue specimens (*n* = 14) and well differentiated HCC tissue specimens (n=14) respectively. (**A**) NOVA1; (**B**) NSMCE2; (**C**) KIAA0196; (**D**) AQP9. ^\#^*P* \< 0.05 *vs* T~MD~ and T~WD~.](oncotarget-08-35973-g003){#F3}

DISCUSSION {#s3}
==========

We have applied the transcriptome sequencing approach to illustrate the gene expression characteristics of poorly differentiated HCC. The number of DEGs for poorly differentiated HCC is significantly bigger than that of other two stages. Those DEGs are enriched in liver tissue and cells, which is easily understood. Pathway analysis showed that two pathways, cell cycle and complement and coagulation cascades, were overrepresented with DEGs. Deregulation of the cell cycle pathway is expected since uncontrolled cell division is the major character of cancer cells. As for the complement and coagulation cascades pathway, consistent with our results, both gene expression \[[@R9]\] and proteomics \[[@R10]\] analysis have shown that this pathway is related to the pathogenesis of HCC. Some transcription factors were found to regulate the DEGs. For example, HNF4-α could represent a central regulator of gene transcription in hepatocytes, and a strong candidate to be involved in liver cancer cell development \[[@R11]\]. In addition, we also compared tumor tissues between PD HCC and MD&WD HCC. And similarly, the differentially expressed genes are enriched in the process of cell cycle and division.

After query of the poorly differentiated HCC signature in the LINCS server in our study, some compounds, knockdown genes and overexpression genes were found to have strong negative connections with the signature. PI-103 is a potent ATP-competitive dual inhibitor of phosphatidylinositol 3-kinase (PI3K) and mTOR (mammalian target of rapamycin). The combination of PI-103 and sorafenib was found to inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways \[[@R12]\]. MK-2206 is an oral selective allosteric inhibitor of Akt that targets all three isoforms of human Akt (Akt-1, Akt-2 and Akt-3). MK2206 was found to inhibit hepatocellular carcinoma cellular proliferation via induction of apoptosis and cell cycle arrest \[[@R13]\]. Among 8 genetic perturbations, 5 genes are enriched in pathways in cancer or PI3K-Akt signaling pathway (p\<0.001). Myc proto-oncogene protein (MYC) as a transcription factor can activate the transcription of growth-related genes. HCC is frequently associated with overexpression of MYC. In this study, MYC is up-regulated in the poorly differentiated HCC. Knockdown of oncogenic KRAS was found to suppress tumor growth in non-small cell lung cancers \[[@R14]\]. As mentioned, AKT2 is the target of MK2206, knockdown and inhibition of AKT2 may both help to reverse HCC. Overexpression of cyclin dependent kinase inhibitor 1B (CDKN1B) has the reverse effect in our study. CDKN1B binds to and prevents the activation of cyclin complexes, and thus controls the cell cycle progression at G1 \[[@R15]\]. All those perturbations may be the potential therapies or targets for treatment of HCC. In the validation cohort, further RT-PCR was performed to validate 4 DEGs specific for poorly differentiated HCC, of which NOVA1, NSMCE2 and KIAA0196 were significantly up-regulated, while AQP9 was significantly down-regulated in poorly differentiated samples, as compared with that in 9 adjacent non-tumor samples, 3 moderately differentiated samples and 3 well differentiated samples. The RT-PCR results showed consistency with RNA-seq. Interestingly, these DEGs were closely related with cell cycle or proliferation. High expression of NOVA1 was found correlated with poor survival rate and increased recurrence rate in HCC \[[@R16]\]. NSMCE2 was required for G1-S transition in breast cancer cells and manipulation of NSMCE2-mediated sumoylation may alter the growth rates of breast cancer cells \[[@R17]\]. KIAA0196, involving in meiosis-related spindle assembly \[[@R18]\], has been showed increased expression in clinical prostate carcinomas and also amplified in 30-40% of xenografts and hormone-refractory tumors \[[@R19]\]. However, AQP9 has been found to be down-regulated in hepatocellular carcinoma and its over-expression suppresses hepatoma cell invasion through inhibiting epithelial-to-mesenchymal transition \[[@R20]\]. In conclusion, this study explored the molecular mechanism of hepatocarcinogenesis through assessment of RNA seq data of HCC and validation of 4 DEGs specific for poorly differentiated HCC in an independent cohort. It provides useful information on the transcriptomic landscape as well as a mechanistic overview of HCC. Our findings offer novel insights and useful support in biomarker development and suggest new potential targets in poorly differentiated HCC characterization.

MATERIALS AND METHODS {#s4}
=====================

Ethics statement {#s4_1}
----------------

Our study design was approved by the Ethics Committee of the Fujian Provincial Hospital. Written informed consent was obtained from all subjects.

Subjects {#s4_2}
--------

47 subjects were diagnosed as primary HCC in the Fujian Provincial Hospital (Table [1](#T1){ref-type="table"}), of which 33 subjects were present with cirrhosis on the non-neoplastic background, including 29 subjects with hepatitis B virus (HBV), 1 subjects with hepatitis C virus (HCV) and 3 subjects with NBNC. HBV related tumors were defined according to the presence of HB surface antigen (HBsAg) in serum, and HCV related tumors were according to the presence of antibody to HCV (HCVAb) in serum. NBNC tumor was defined according to the absence of both HBsAg and HCVAb in serum. Primary tumor and adjacent non-tumorous samples were obtained from all patients who underwent surgical tumor resection. All samples were frozen immediately at −80°C until RNA extraction. Total RNA was isolated by using RecoverAll™ Total Nucleic Acid Isolation Kit (Life Technologies, Carlsbad, CA, USA). Integrity of RNA was assessed by Agilent 2100 bioanalyzer (Agilent, Santa Clara, CA, USA). RNA from nine samples was subjected to sequencing and all samples were used in the validation experiments.

Transcriptome sequencing {#s4_3}
------------------------

Sequencing libraries were prepared by using *TruSeq RNA Sample Prep Kit (Illumina, San Diego, CA, USA)* according to standard protocols. Briefly, total RNA was firstly randomly fragmented and poly-A-selected. Secondly, the RNA fragments were reverse transcribed to cDNA, end-repaired and ligated with adapters. The libraries then underwent size selection, PCR and purification. The quality of libraries was assessed by using Bioanalyzer 2100 (Agilent, Santa Clara, CA, USA). Sequencing was then performed on an Illumina HiSeq2500 sequencer with 125 bp pair-end reads.

Reads processing {#s4_4}
----------------

Raw sequencing reads were firstly filtered for adapters and ribosomal RNA. Reads containing five or more low quality (quality score \< 20) bases were also removed. The remained high-quality reads were then aligned to human genome (hg19) by using Tophat \[[@R21]\]. The mapped reads were then subjected to alignment against the human transcriptome (Ensembl, GRCh37.73). Gene expression level measured by FPKM (fragments per kilobase per million) was calculated by Cufflinks \[[@R22]\].

Differentially expressed genes (DEGs) analysis {#s4_5}
----------------------------------------------

For each differentiated HCC group, DEGs between the tumor and matched non-tumorous tissues were identified with pair-wise *t* test and the significant threshold was set as adjusted *p-value* of less than 0.05 and \|log~2~(fold change, FC)\| \> = 1. Enrichr was used to do functional enrichment analysis like Gene Ontology (GO) and KEGG pathway \[[@R7]\]. The significant threshold for enrichment was set as *p* \< 0.1. In addition, the list of up-regulated genes and down-regulated was uploaded into lincscloud \[[@R8]\] to find perturbations which can reverse the cancer condition. Using similar methods (*t* test instead of paired *t* test), DEGs were identified and analyzed between tumor tissues of PD HCC and those of MD&WD HCC.

DEGs specific for poorly differentiated HCC validated by RT-PCR {#s4_6}
---------------------------------------------------------------

DEGs specific for poorly differentiated HCC (Compared with 3 matched adjacent non-tumor tissue of poorly differentiated HCC, P\<0.05, \|log~2~(fold change, FC)\| \> = 1; Compared with all adjacent non-tumor tissue, 3 moderately differentiated tissue and 3 well differentiated tissue, P\<0.05, \|log~2~(fold change, FC)\| \> = 1) were subjected to validation using RT-PCR. The validation cohort included 15 poorly differentiated HCC, 18 moderately differentiated HCC and 14 well differentiated HCC (Table [1](#T1){ref-type="table"}). For the RT-PCR reactions, total RNA was converted to cDNA with random hexamer primers using the High-Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City, CA, USA). Real-time PCR was performed with SYBR Green I (Applied Biosystems, United States) on ABI 7300 (Applied Biosystems). The primers used were described in Table [6](#T6){ref-type="table"}.

###### Primers used in this study

  Gene       Primers (5′--3′)              Length (bp)
  ---------- ----------------------------- -------------
  NOVA1      GACCAATACGGGCGAAGACG          295
             CTGGGGTTGTAGAATGCTGACTG       
  NSMCE2     AGACCAACTTCACCTGCCCC          131
             CTTTTTCTTCCGCTTTTGCCTG        
  KIAA0196   GAGGGAGGGGTGGAAACTGG          208
             ATTGTGAGGCGGACCGACTAC         
  AQP9       TGGAGGGGTCATCACTATCAAT        226
             CATAAGTCCATCATAGTAAATGCCAAA   

Statistical analysis {#s4_7}
--------------------

*T-test* was used to compare continuous measurement data with a normal distribution between two groups. Mann-Whitney *U* test was used to evaluate continuous data with a non-normal distribution. Statistical analyses were performed with the SPSS13.0 software (SPSS, United States). *P* \< 0.05 was considered statistically significant.
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HCC

:   hepatocellular carcinoma

PD

:   poorly differentiated

MD

:   moderately differentiated

WD

:   well differentiated

DEGs

:   differentially expressed genes

GO

:   Gene Ontology

*KEGG*

:   Kyoto Encyclopedia of Genes and Genomes

PI3K

:   phosphatidylinositol 3-kinase

Akt

:   protein kinase B

mTOR

:   mammalian target of rapamycin

MAPK

:   mitogen activated kinase-like protein

MYC

:   Myc proto-oncogene protein

CDKN1B

:   cyclin dependent kinase inhibitor 1B

FPKM

:   fragments per kilobase per million

HBV

:   Hepatitis B virus

HBsAg

:   HB surface antigen

HCV

:   Hepatitis C virus

NBNC tumor

:   non-B non-C tumor

NOVA1

:   NOVA alternative splicing regulator 1

NSMCE2

:   NSE2/MMS21 homolog, SMC5-SMC6 complex SUMO ligase

AQP9

:   aquaporin 9
